It was shown that SGLT2 inhibitors decrease the levels of proinflammatory cytokines in patients with type 2 diabetes, as well as the activity of NLRP3 inflammasome [29,30,31,32]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.